The 36-month beta value for PBM is at 0.14.
The public float for PBM is 0.09M, and currently, shorts hold a 44.60% of that float. The average trading volume for PBM on June 18, 2025 was 85.43K shares.
PBM) stock’s latest price update
The stock price of Psyence Biomedical Ltd (NASDAQ: PBM) has jumped by 16.61 compared to previous close of 4.36. Despite this, the company has seen a fall of -2.49% in its stock price over the last five trading days. newsfilecorp.com reported 2025-06-17 that New York, New York–(Newsfile Corp. – June 17, 2025) – Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) today announced that it has received formal notification from the Nasdaq Hearings Panel confirming that the Company has regained compliance with all applicable Nasdaq continued listing requirements.
PBM’s Market Performance
Psyence Biomedical Ltd (PBM) has seen a -2.49% fall in stock performance for the week, with a -2.12% decline in the past month and a -7.58% plunge in the past quarter. The volatility ratio for the week is 10.05%, and the volatility levels for the past 30 days are at 8.16% for PBM. The simple moving average for the past 20 days is 4.09% for PBM’s stock, with a -82.11% simple moving average for the past 200 days.
PBM Trading at 17.34% from the 50-Day Moving Average
After a stumble in the market that brought PBM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.27% of loss for the given period.
Stock Fundamentals for PBM
The total capital return value is set at 0.5.
Based on Psyence Biomedical Ltd (PBM), the company’s capital structure generated 2.01 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at -1.99. The interest coverage ratio of the stock is -170.15.
Currently, EBITDA for the company is -2.75 million with net debt to EBITDA at -1.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.64.
Conclusion
In conclusion, Psyence Biomedical Ltd (PBM) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
